Use of fondaparinux (ARIXTRA(R)) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II
Open Access
- 26 January 2005
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (2) , 444-446
- https://doi.org/10.1093/ndt/gfh544
Abstract
We report the successful use of fondaparinux in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II (HIT II). HIT II complicates the choice of an optimal anticoagulant in dialysis patients.Keywords
This publication has 7 references indexed in Scilit:
- Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary EmbolismNew England Journal of Medicine, 2004
- Heparin-induced thrombocytopenia: Pathophysiology and new treatment optionsPathophysiology of Haemostasis and Thrombosis, 2002
- Drug development for neglected diseasesThe Lancet, 2002
- Hirudin versus heparin for anticoagulation in continuous renal replacement therapyIntensive Care Medicine, 2001
- Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoidPediatric Nephrology, 2000
- In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgeryJournal of Clinical Anesthesia, 2000
- Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in ManThrombosis and Haemostasis, 1995